Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered Myricx Bio for up to $1.5 billion, with $1.1 billion paid up front and up to $400 million tied to milestones. The deal brings Myricx’s experimental N‑myristoyltransferase inhibitor (NMTi) antibody‑drug conjugate (ADC) payload platform into Novartis’s oncology portfolio. Myricx lists a U.S. presence in Boston, and the companies expect the transaction to close in the second half of 2026, pending customary approvals.
Deal Terms And Company Statements
According to a Novartis press release, the Swiss drugmaker will pay $1.1 billion in cash at closing and could pay as much as $1.5 billion including milestone payments, describing the buy as a way to expand its next‑generation oncology platforms. Novartis said the transaction is expected to close in H2 2026, subject to customary conditions.
What Myricx Brings
Myricx was spun out of Imperial College London and the Francis Crick Institute and has built a pre‑clinical ADC pipeline centered on NMT inhibition, with lead assets aimed at B7‑H3 and HER2, according to Imperial College London. Company leaders say the platform is designed to offer a payload mechanism that could help address resistance and tolerability limits seen with some existing ADC classes. In other words, the science is still early, but the pitch is that this payload could hit tumors that current ADCs struggle with while being easier on patients.
Boston Connection And Local Impact
Myricx lists a U.S. presence in Boston, and local reporting notes that Novartis already maintains a substantial footprint in Cambridge, a combination that keeps the deal squarely on the radar of the region’s life‑science labor market and investors. As reported by the Boston Business Journal, Boston is where Myricx has established its U.S. team and where observers expect any follow‑on hiring or partnerships to show up.
Why The Payload Matters
Novartis said the NMTi payload platform could broaden ADC activity across solid tumors by providing an orthogonal mechanism of action to payload classes such as TOPO‑1 and tubulin inhibitors, potentially improving effectiveness and tolerability. That rationale, along with the sector’s broader push for differentiated payload chemistries, helps explain why big pharma has been paying premiums for small, platform‑focused biotechs that are still in the pre‑clinical stage.
Investor View And Funding History
Myricx raised roughly £90 million (about $114 million) in a 2024 Series A co‑led by Novo Holdings and Abingworth, according to Novo Holdings and earlier investor announcements. Brandon Capital and other backers have described the exit as validation for the team’s science and for early‑stage UK oncology investing, a relatively small but closely watched corner of the global biotech market.
Next Steps To Watch
Reporting notes the deal remains subject to regulatory sign‑offs and customary closing conditions, with an expected timetable in the second half of 2026. Local watchers will be keeping an eye on whether Novartis folds the Boston team into its existing Cambridge labs or opts to expand its area operations as it advances the NMTi programs through development. Either way, the region’s biotech scene just picked up another nine‑figure headline deal to talk about.
